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Uremic cardiomyopathy: an inadequate left ventricular hypertrophy.
Echocardiographic study of the left ventricle was performed in 57
selected, normotensive hemodialysis patients in comparison to 40
healthy controls matched for sex, age and blood pressure. The statis-
tically significant abnormalities in uremic patients were an enlargement
of the left ventricular end—diastolic diameter (LVED1D) (5.58 0.60 vs.
5.05 0.5 cm; P < 0.001) and an increase in the left ventricular radius
to posterior wall—thickness ratio (r/Th) (3.65 0.68 vs. 3.27 0.44; P
<0.001). Enlargment of the ventricle was related to anemia (P < 0.001)
and the hemodynamic effect of arteriovenous fistula. Ventricular radius
to wall thickness ratio was inversely related to systolic arterial pressure
in controls (P < 0.001) and patients (P < 0.01) with a significant upward
shift of the regression in dialysis patients (P < 0.001). In dialysis
patients, the left ventricular posterior wall thickness (LVPWT) was
inversely correlated to serum parathormone (PTH) level (P < 0.001),
and r/Th ratio was positively correlated to serum PTH (P <0.001).
Bone biopsy was performed in 28 patients. Histomorphometric indexes
of osteitis fibrosa were in dialysis patients, correlated to echocar-
diographic abnormalities; osteoclasts number was inversely correlated
to LVPWT (P < 0.001) and positively related to r/Th ratio (P < 0.001).
Osteoclastic resorption surfaces and LVPWT were inversely correlated(P < 0.001), while a positive correlation between r/Th ratio and
osteoclastic resorption surfaces was observed (P <0.001). Osteoblastic
surfaces and tetracycline double—labeled surfaces were also correlated
to LVPWT (P < 0.001) and r/Th ratio (P < 0.001). During longitudinal
survey, a decrease in LVPWT with an increase in r/Th ratio was
observed only in dialysis patients with bone histologic signs of active
secondary hyperparathyroidism. Our findings suggest that inadequate
left—ventricular hypertrophy is, in dialysis patients, associated with the
severity and progression of secondary hyperparathyroidism. The he-
modynamic significance of these abnormalities is not clear, since
functional indices of left ventricular function remain within the normal
range.
Various factors that may adversely affect cardiac functions
are present in uremic patients [1]. Thus, though intrinsic
"uremic" myocardial involvement has been postulated [2, 31,
conclusive evidence supporting the uremic factor as a cause of
myocardial involvement is lacking. This may be due to the
frequent association of uremia with other complicating condi-
tions, such as hypertension, coronary artery disease, hyperlip-
Received for publication January 15, 1986
and in revised form May 21 and September 11, 1986
© 1987 by the International Society of Nephrology
idemia and others [1]. This makes the evaluation of the uremic
factor difficult. However, experimental studies have shown that
uremic toxins are capable of depressing the myocardial function
[4, 5]. In addition, parathyroid hormone (PTH) may be a potent
uremic toxin [6] which, in experimental conditions, has several
adverse effects on myocardium cell functions and metabolism
[7—9]. Furthermore, in dialysis patients secondary hyperpara-
thyroidism has been implicated in the pathogenesis of left
ventricular dysfunction [10, 11]. The purpose of the present
study was to assess in dialysis patients, the relationships
between the magnitude of secondary hyperparathyroidism and
the cardiac morphology and function.
Methods
One—hundred and sixteen patients on maintenance dialysis
were evaluated for at least 18 months. Patients were on dialysis
from 19 to 196 months (87.6 50.2).
Patients were hemodialyzed using hollow fibers dialyzers,
whose surfaces (1.2 to 2.0 m2) were matched to patient's body
surface area. The patients were treated three times weekly, and
the duration of dialysis was individually tailored (4 to 5 hours)
to control body fluids and to keep the predialysis serum urea
less than 30 mmollliter, serum creatinine less than 1.1
mmol/liter and to maintain serum electrolytes in normal range.
Water supply was treated with reverse osmosis. Dialysate was
delivered by systems including bicarbonate delivery and ultra-
filtration devices. In all patients an internal arteriovenous fistula
was used for dialysis. Phosphates binders were given when
necessary in order to maintain pre-dialysis phosphate concen-
tration < 1.8 mmollliter. None was taking cardiovascular drugs.
Forty healthy subjects were studied as controls; they had renal
function, blood and urinary chemistry within the normal range.
Their long—term blood pressure profile was evaluated on the
basis of twice—monthly blood pressure measurements over a
period of three months. The average value of the six measures
(in supine position) was taken for each subject. Their cardio-
vascular status was normal as evaluated by clinical history,
ECG, and chest X-ray. None was taking cardiovascular drugs.
All patients and control subjects gave informed consent.
Echocardiographic studies were performed 15 to 20 hours
after the mid—week hemodialysis. In order to evaluate the
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hemodynamic effect of the A-V fistula, it was repeated after 10
minutes of manual occlusion of the fistula. Two dimensional
echography was performed using Roche Kontron R.T. 400
apparatus, M-mode echography was done with an IRREX
ultrasonograph using a 2.25 MHz transducer and a Cardio 80
Hewlett Packard computer (Elkhart, Indiana, USA). Echocar-
diograms were obtained with the patients in semi-recumbent
and left lateral positions from an echocardiographic window
located in the third or fourth intercostal space at the left sternal
border. Echocardiographic data were analyzed following the
recommendations of the American Society of Echocardiogra-
phy [12]. Basic echocardiographic measurements included left
ventricular end—diastolic (LVEDiD) and end—systolic diame-
ters, interventricular septal thickness (IVST) and left
ventricular posterior wall thickness (LVPWT). All echocar-
diographic measurements were calculated on 10 to 15 high
quality cycles. Ventricular volumes were calculated from a
regression equation described by Teicholz et al [13], and stroke
volume, cardiac output, and ejection fraction were determined
[13]. M-mode, echographic aortic—valve motion was used to
assess the left ventricular ejection time. The mean velocity of
circumferential fiber shortening was calculated using the
method of Cooper et al [14]. The same observer performed all
echocardiographic measurements.
Patients were excluded from the study who had: 1) a history
of angina pectoris, myocardial infarction and/or congestive
heart failure; 2) valvular diseases; 3) diabetes, systemic dis-
eases, blood lipid abnormalities and iron overload; 4) left
ventricular regional wall motion abnormalities (identified by
two dimensional echocardiography); 5) a history of essential or
malignant hypertension; 6) the presence of hypertension while
on dialysis, that is, patients whose blood pressure was not
controlled with ultrafiltration during dialysis and needed
antihypertensive therapy. Blood pressure was determined in
each patient by averaging his supine pre- and post-dialysis
blood pressure over a period of six months preceding the
echocardiographic study. Eight patients were excluded because
their echo tracings were technically unsatisfactory. Thus, after
the initial evaluation of 116 patients, 57 were studied. They
included 29 women and 28 men. Of these patients, though 36
had a history of moderate hypertension during the terminal
phase of their nephropathy, all became normotensive with
dialysis therapy.
Thirty controls (15 women and 15 men) and 44 hemodialysis
patients gave their consent for a blood volume estimation using
isotopic dilution method with radioiodinated albumin [15]. After
withdrawal of blood samples, 3 pCi were injected. Consecutive
blood samples were taken 5, 10, 15 minutes after and activity
plotted against time. The plasma volume was calculated from
the extrapolated activity at zero time. Blood volume was
determined from plasma volume and peripheral hematocrit.
Blood volume was expressed in mum2.
Magnitude of secondary hyperparathyroidism was evaluated
by determination of plasma PTH concentration and by bone
assessment of the histologic signs of osteitis fibrosa. In all 57
patients studied, blood samples were taken prior to blood
volume measurements. Parathyroid hormone was determined
by radioimmunoassay (Kit H PTH-C-K, Compagnie ORIS
Industrie) using a specific 53-84 antiserum against a large
C-terminal fragment of synthetic human parathormone [16].
The values obtained in normal population range from 20 to 90
pg/ml (54.5 17.7 pg/ml). Of the 57 patients studied, 28 gave
their written consent and had an anterior iliac—crest bone
biopsy. Bone biopsy was performed after double tetracycline
labeling according to the schedule of two days on tetracycline,
10 days off, and two days on. On three 5 sections stained by
toluidin blue, trabecular bone volume (%), osteoid surfaces and
volume (%), osteoblastic surfaces (%), osteoclastic resorption
surfaces (%), osteoclasts/mm2, were measured. On two un-
stained 10 j. thick sections, mineralization rate and extend of
single or double labeled surfaces (%) were measured. All
measurements were performed with an eye—piece graticule
(Zeiss integral plate II, Zeiss, Oberkochen, FRG). Patients in
which the osteoclastic bone resorption surface [17] was supe-
rior to 1% were considered to have an osteitis fibrosa.
Follow—up study
Twelve control subjects and 22 dialysis patients were studied
again at 18 to 36 months after the initial study. All 22 patients
had a bone biopsy during the initial study; 10 had an increased
bone resorption surface (>1%) and 12 had a normal bone
resorption surface. During the follow—up time interval, all
dialysis patients had pursued the same therapeutic strategy and
had not received any drug treatment with cardiovascular im-
pact. The echocardiographic study of the left ventricle and the
measurements of humoral parameters were repeated. All echo-
cardiograms were performed and evaluated by the same inves-
tigator as in the first study.
Statistical study
Results are given as the mean values SD. Student's t-test
for paired and unpaired data and analysis of variance were used
for statistical analysis. Univariate and multivariate regression
analysis were used for correlations studies. Covariance analysis
was used to estimate the differences in the correlations.
Results
The clinical and echocardiographic data of the 40 normal
controls and 57 hemodialysis patients are summarized in Table
I. The left ventricular end-diastolic (LVEDID) and end—systol-
ic (LVESD) internal diameters were significantly larger in
dialysis patients. Arteriovenous fistula occlusion reduced
LVEDiD from 5.58 0.6 cm to 5.50 0.62 cm (P <0.01), but
did not change the LVESD (3.32 0.53 cm vs. 3.36 0.52cm).
Left—ventricular posterior wall—thickness and interventricular
septal thickness were similar in controls and patients. Arterio-
venous fistula occlusion did not modify the thickness of the
posterior wall (0.76 0.15 cm fistula opened vs. 0.77 0.15 cm
fistula closed). The thickness of the interventricular septum was
not modified after arteriovenous fistula occlusion. Ejection
fraction and velocity of circumferential fiber shortening were
similar in controls and dialysis patients. Arteriovenous fistula
occlusion induced a significant fall in cardiac output (from 7985
1751 mllmin to 7169 1578 mI/mm; P < 0.001), in ejection
fraction (from 69.7 9.7% to 67.6 6.8%; P < 0.001), and in
the velocity of circumferential fiber shortening (from 1.32
0.30 circle/sec to 1.24 0.29 circle/sec; P < 0.01).
In the control subjects, the LVEDiD was correlated with
subjects' body surface area (r = 0.62; P < 0.001) and age (r =
0.45; P < 0.005). In dialysis patients, the LVEDiD was in-
Table 1. Clinical and echocardiographic data
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Control
subjects
Hemodialysis
patients
P value
<
Number of patients 40 57
Sex men/women 19/21 28/29
Age years 45 10.1 48.7 13.5 NS
Body surface area m2 1.80 0.19 1.63 0.23 0.001
Systolic pressure mm Hg 137 15.8 138 12.1 NS
Diastolic pressure mm Hg 81 8.85 78 6.04 NS
LVEDiD cm 5.05 0.5 5.58 0.60 0.001
LVESD cm 3.12 0.44 3.32 0.53 0.01
LVPWT cm 0.77 0.13 0.76 0.15 NS
IVST cm 0.89 0.14 0.86 0.23 NS
r/Th ratio 3.27 0.44 3.65 0.68 0.001
Ejection fraction % 66.8 5.1 69.7 9.7 NS
VCF circle/sec 1.25 0.20 1.32 0.30 NS
Blood volume mI/rn2 2833 498 2880 785 NS
Values are mean 5D
Abbreviations are: LVEDiD, left ventricular, end—diastolic diameter;
LVESD, left ventricular, end—systolic diameter; LVPWT, left ventric-
ular, posterior wall thickness; IVST, interventricular septal thickness;
r/Th, left ventricular radius to wall thickness ratio; VCF, velocity of
circumferential fiber shortening; NS, non-significant.
versely correlated with hemoglobin level (r =
—0.60; P <0.001)
and hematocrit (Ht) (r =
—0.62; P < 0.001) (Fig. 1). The
LVEDiD was positively correlated with hemodynamic effect of
arteriovenous fistula occlusion, expressed in terms of changes
in cardiac output and/or changes in cardiac index—ACI
(liter mm . m) (r = 0.50; P < 0.001). In dialysis patients,
multivariate analysis indicated that there was a correlation
between LVEDiD, degree of anemia and arteriovenous—fistula
occiussion effect (r = 0.71; P < 0.001), according to the
regression:
LVEDiD (cm/rn2) = 4.02 — 0.29 Ht + 0.4 zCI
In dialysis patients, the LVEDiD was not correlated with blood
volume, blood pressure and circulating parathormone level.
LVEDiD and duration of dialysis treatment were not correlated
(r = 0.16; NS).
In control subjects, the LVPWT was correlated with systolic
pressure (r = 0.72; P < 0.001). Although in hernodialysis
patients a similar positive correlation between LVPWT and
systolic pressure was observed (r = 0.32; P < 0.02), compared
with the control group it was significantly different (F1,95 = 16.8;
P < 0.001). In dialysis patients, there was no correlation
between left—ventricular posterior wall—thickness and hemoglo-
bin level or hematocrit. A positive but non-significant correla-
tion was observed between LVPWT and duration of dialysis (r
= 0.25; NS). Changes in cardiac output or index induced by
arteriovenous fistula occlusion were not correlated to the
LVPWT (r = 0.08; NS). Left ventricular radius to wall thick-
ness ratio (r/Th) was inversely correlated with systolic arterial
pressure in controls (r =
—0.83; P < 0.001) and hemodialyzed
patients (r = —0.41; P < 0.005) (Fig. 2). Figure 2 displays a
significant upward reseting of the mean regression line in
dialysis patients (F195 = 17.2; P < 0.001). In these patients,
there was not a correlation between ventricular radius to wall
thickness ratio and duration of dialysis therapy by the degree of
anemia or arteriovenous—fistula occlusion effect.
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Blood chemistry and bone histomorphometric data are sum-
marized in Table 2. Patients on hemodialysis presented a
significant increase in alkaline phosphatase and in serum phos-
phates. Immunoreactive parathormone (iPTH) was markedly
increased in hemodialysis patients. In patients, there was an
inverse correlation between the levels of iPTH and the left
ventricular, posterior wall thickness (r = —0.46; P < 0.01). In
hemodialysis patients, multivariate analysis showed that
LVPWT (cm/rn2) = 0.45 + 0.003 systolic pressure — 0.169 Log
iPTH (r = 0.74; P < 0.001). There was no correlation between
serum iPTH and blood pressure, hemoglobin level or hemato-
crit. However, serum iPTH was positively correlated to left
ventricular radius to wall thickness ratio (r = 0.48; P < 0.001).
Multivariate analysis indicated that in dialysis patients r/Th
(ratio) = 3.86 — 0.02 systolic pressure + 1.09 Log iPTH (r =
0.65; P < 0.001).
The histomorphometnc data of the 28 biopsied hemodialysis
subjects are shown in Table 2. Overt secondary hyperpara-
thyroidism (osteoclastic resorption surfaces >1%) was present
in 16 patients, while in twelve patients the bone resorption was
within the normal range or low (Fig. 3). In these 12 subjects the
serum iPTH was significantly increased when compared to the
control normal population (155 75 pg/ml vs. 54.5 17.7
pg/ml; P < 0.001), but was significantly lower than the iPTH in
the 16 patients with increased bone resorption surfaces (443
171 pg/ml; P < 0.001). Dialysis patients with normal or low
bone resorption had a significantly larger LVPWT than patients
with overt hyperparathyroidism (0.71 0.10 cm vs. 0.91 0.09
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Fig. 1. Relationship between hematocrit and left ventricular end—dia-
stolic internal diameter in hernodialysis patients. (r = —0.62, P < 0.001)
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Table 2. Blood chemistry and bone histomorphometry in controls
and dialysis patients
Dialysis
Controls patients P value
Hemoglobin, mmol/liter 8.8 0.8 5.45 2.26 0.001
Hematocrit, % 43.4 3.2 26,8 9.06 0.001
Calcium, inmol/liter 2.38 0.06 2.41 0.08 NS
Phosphates, mmoiliiter 1.10 0.30 1.48 0.71 0.001
Alkaline phosphatase,
nKat/liter 701 97 1173 659 0.001
Parathormone, pg/mi 54.5 17.7 317.8 230.3 0.001
Relative osteolda volume, % 2 1 7 3.8 0.001
OsteoId surfaces, % 15 5 49.8 18.1 0.001
Osteoclasts/mm2a 0.15 0.05 1.50 1.53 0.001
Osteoclastic resorption
surfaces, % 0.4 0.3 2.08 1.85 0.001
Osteoblastic surfaces, % 4 2.0 8.0 6.7 0.01
Tetracycline double—labeled
surfaces, % 5 0.6 9.85 10.7 0.02
a the statistical analysis of bone histomorphometry is based on a
study of 23 control subjects and 28 dialysis patients.
cm; P < 0.001). In dialysis patients with normal or low bone
resorption, the left ventricular radius to wall thickness ratio was
lower than in dialysis patients with overt hyperparathyroidism
(3.13 0.29 vs. 4.06 0.61; P < 0.001). Left ventricular
diameters were similar in these two "subgroups". In fact when
all 28 subjects were studied together, significant correlations
were observed between bone histomorphometric indices of
osteitis fibrosa and echocardiographic parameters (Fig. 3 and
Table 3).
Follow—up study
A second echocardiographic study was done in a group of 12
normal control subjects after 12 to 36 months. In this control
group, LVEDiD did not change during the follow—up period
(4.92 0.41 vs. 4.80 0.43). During this period, LVPWT
remained the same (0.85 0.14 vs. 0.83 0.12). Ejection
fraction and velocity of circumferential fiber shortening did not
change during the follow—up in the normal control subjects.
Data summarizing the results of the follow—up study in 22
hemodialyzed patients are summarized in Table 4. A small
increase in circulating iPTH was observed in patients who had
an increased bone resorption. Left ventricular end—diastolic
diameter did not change during the follow—up period. As shown
in Figure 4 and Table 4, a significant decrement of ventricular
posterior wall—thickness occured only in patients with histology
signs of osteitis fibrosa, while in patients with no histological
evidence of increased bone resorption there was no change in
LVPTWT, and even an increment was observed in some
patients. A weak correlation was observed between changes in
serum iPTH level and the changes in LVPWT in the overall
population of dialysis patients. A significant increase in left
ventricular radius to wall thickness ratio occurred in dialysis
patients with increased bone resorption (Table 4). The func-
tional indices of cardiac function remained stable in both groups
of hemodialyzed patients.
Discussion
In the present study, echocardiographic evaluation in
hemodialysis patients indicates the presence of an increased left
ventricular diameter, with an absence of compensatory thick-
ening of left ventricular wall—thickness. This results in an
increase in left ventricular radius to wall thickness ratio, which
is inadequately high for a given systemic arterial pressure. The
degree of the abnormality in the relationship between left
ventricular wall—thickness and diameter is associated with the
severity and evolution of secondary hyperparathyroidism as
evaluated by the serum level of iPTH or bone histologic signs of
osteitis fibrosa.
Enlargement of the left ventricle is a common finding in
hemodialysis patients [11, 18, 19]. These heart dimensional
changes seem to be related to hemodynamic abnormalities
usually associated with uremia, i.e. anemia and dialysis fistula.
The available data do not support fluid volume overload as an
important factor in these abnormalities. However recent studies
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Table 3. Coefficients of correlation between bone histomorphometry, echocardiographic measurements, and serum parathormone level
Left ventricular posterior
wall thickness cm/rn2
Left ventricular radius
to wall thickness ratio
Parathormone level
pg/mi
Relative osteoid volume % r = —0.18; P = NS r = 0.13; P = NS r = 0.28; P = NS
Osteoidsurfaces% r = 0.19;P = NS r = 0.17;P = NS r = 0.l1;P = NS
Osteoclasts/mm2 r = —0.80; P < 0.001 r = 0.72; P < 0.001 r = 0.71; P < 0.001
Osteoclastic resorption surfaces % r = —0.79; P <0.001 r = 0.78; P < 0.001 r = 0.80; P < 0.001
Osteoblastic surfaces % r = —0.64; P < 0.001 r = 0.62; P < 0.001 r = 0.74; P < 0.001
Tetracycline double-labeled surfaces % r = —0.64; P < 0.001 r = 0.59; P < 0.001 r = 0.71; P < 0.001
have shown that ultrafiltration treatment during dialysis reduces
the ventricular size [18, 20, 21].
In the present study, while there is an increased dimension of
the left ventricular cavity, the left ventricular wall thickness
remains normal. This is in apparent contradiction with some
previous studies, showing thickening of the left ventricular wall
as a frequent finding in hemodialysis patients [19, 20, 22].
Probably the criteria for selection of patients may be responsi-
ble for such apparent discrepancies. Thus, in these studies,
patients were selected randomly, including treated hyperten-
sive patients and patients with various cardiovascular abnor-
malities. In addition, a control group matched for sex, age and
blood pressure was not included. This is an important consid-
eration, since even in normal population the range of blood
pressure is a major determinant of the left ventricular thickness
[23]. Thus a constant relationship between blood pressure and
the ventricular chamber radius to wall thickness ratio is main-
tained in normal growing children [24], adults with normal
hearts, trained athletes [25], normal pregnant women [26] and
cardiac patients with compensated, chronic left—ventricular
volume—overload [27, 28]. In these situations it is important to
evaluate whether the left ventricular muscle—mass is appropri-
ate for the chamber size. Hemodynamically this can be as-
sessed by evaluating the relationship between the left
ventricular end—diastolic radius to posterior wall thickness ratio
and left ventricular systolic—pressure [23]. Such a correlation
was observed in the present study, both in controls and patients
(Fig. 2). However, patients have a higher radius to thickness
ratio for a given systolic pressure, which resulted in an upward
shift of the mean regression line; this implies an inadequate
hypertrophy of the left ventricle [23]. The functional impor-
tance of this inadequate hypertrophy does not seem to be
clinically important since a normal ejection fraction and veloc-
Table 4. Follow—up study in dialysis patients with increased bone
resorption (Group A, N = 10), and patients with normal bone
resorption (Group B, N 12)
Group A Group B P value
Systolic pressure First study 144 11.9 140.5 10.8 NS
mm Hg Follow—up
P value
149.4 12.7
NS
136.1 13
NS
NS
Hemoglobin, First study 5.42 2.17 5.13 2.07 NS
mmol/liter Follow—up
P value
5.27 2.23
NS
5.28 2.42
NS
NS
Parathormone, First study 424 168 155 73 0.001
pg/mi Follow—up
P value
518 211
0.05
142 77
NS
0.001
LVEDiD, cm First study
Follow—up
P value
5.60 0.38
5.70 0.50
NS
5.61 0.49
5.63 0.64
NS
NS
NS
LVPWT, cm First study
Follow—up
P value
0.78 0.14
0.65 0.16
0.02
0.91 0.09
0.90 0.09
NS
0.05
0.01
IVST, cm First study
Follow—up
P value
0.90 0.14
0.81 0.14
NS
1.01 0.12
0.94 0.14
NS
NS
NS
r/Th, ratio First study
Follow—up
P value
3.61 0.61
4.49 1.19
0.01
3.13 0.29
3.29 0.46
NS
0.05
0.001
Ejection First study 68.3 6.4 69.5 3.5 NS
fraction, % Follow—up
P value
65.8 7.7
NS
64.0 7.3
NS
NS
VCF, circle sec First study
Follow—up
P value
1.23 0.20
1.27 0.18
NS
1.21 0.19
1.13 0.18
NS
NS
NS
For abbreviations see Table 1.
ity of circumferential fiber shortening was observed, both in
basal conditions and after arteriovenous fistula occlusion. Mod-
erate impairment in cardiac function was observed in 18% of the
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Fig. 4. Changes in parathormone level and left
ventricular posterior wall thickness during follow—up
period (A). Changes in parathormone level and left
ventricular diameter during follow—up period (B).
Patients with normal bone resorption are symbolized by
full circles (•); patients with increased bone resorption
are symbolized by open circles (0).
the circulating iPTH and left ventricular wall—thickness, and a
significant positive correlation between iPTH and r/Th ratio.
Nevertheless, secondary hyperparathyroidism defined on the
basis of serum PTH is an almost universal finding in uremic
patients, whether or not they have signs of tissue and organ
damages attributable to PTH excess [41]. Therefore, an in-
creased PTH level could well be an index of hyperpara-
thyroidism or an index of uremia. For the definition of an active
hyperparathyroidism, histologic bone lesion of osteitis fibrosa
are more valuable. From this point of view the relationship
existing in dialysis patients between the histologic signs of
osteitis fibrosa and echocardiographic left—ventricular abnor-
malities are more suggestive. While the patients with increased
bone resorption have the same enlargement of the left ventric-
ular diameter as dialysis patients with normal bone resorption,
the former patients have a higher radius to wall thickness ratio
which is due to a significantly—decreased posterior wall—thick-
ness. Furthermore, in the overall dialysis population, significant
relationships are observed between bone lesions characteristic
of secondary hyperparathyroidism and echocardiographic pa-
rameter characteristic of inadequate hypertrophy (Fig. 3, Table
3). Aluminium has been reported to be toxic to myocardium
[42], but the high percentage of tetracycline double—labeled
surfaces would suggest that aluminium intoxication was not
significant in our hyperparathyroid patients. Furthermore, an
inverse relationship usually exists in dialysis patients between
secondary hyperparathyroidism and aluminium overload [43].
Therefore aluminium intoxication could be associated with
adequate rather than inadequate hypertrophy. Such hypothesis
should be verified in future studies. The results of the follow—up
study, even if limited by the small number of patients and
relatively short duration of the observation, tend to confirm the
results of the cross sectional design. The echocardiographic
abnormalities suggestive of inadequate hypertrophy become
more apparent in patients with bone histology signs of osteitis
fibrosa (Table 4) and a weak, but significant inverse correlation
is observed between the variations of PTH level and dimen-
sional changes of the left ventricular wall. Yet, the functional
indexes of left ventricular function remain within the normal
range, and no correlations are observed between changes in
PTH and variations of ejection fraction or velocity of circum-
ferential fiber shortening.
The histological action of PTH in dialysis patients regarding
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patients. This is a lower frequency than that observed in
previous studies [11, 291. Indexes of cardiac function are, to a
large extent, influenced by the dialysis procedure itself [18—20,
30], making the assessment of the cardiac status and the
comparison between different studies difficult. Another possi-
bility is that patient selection may have determined the lower
incidence of cardiac functional abnormalities observed in this
study.
Coronary artery disease cannot be completely excluded as
the cause of the indadequate ventricular hypertrophy observed
in dialysis patients, but it has been shown that in dialysis
patients in the absence of anginal symptoms the coronary
arteries are usually not significantly altered [31, 32]. In addition,
the role of blood viscosity as a determinant of cardiac hyper-
trophy in normotensive or essential hypertensive patients has
been recently emphasized by Devereux et al [33]. In chronic
uremia, the anemia is almost constant, and is responsible for a
decrease in blood viscosity and total peripheral resistances [34].
However, in the present study neither wall thickness nor r/Th
ratio were related to hematocrit or hemoglobin level.
The possibility exists that cardiac abnormalities observed in
patients on maintenance dialysis are related to uremia per se.
Indeed, experimental studies have shown that uremic serum
has depressant cardiac effects [4, 5], but the specific uremic
toxin has not been identified.
Parathyroid hormone has been postulated as an important
uremic toxin [61. Thus experimental data indicate that PTH may
have a direct effect in the myocardium. Studies in animals have
demonstrated that in uremic animals, parathyroidectomy pre-
vents the appearance of increased myocardial calcium content,
calcium deposits, myocardial cells necrosis and myocardial
tissue fibrosis [35—37]. In hemodialysis patients, secondary
hyperparathyroidism has been implicated in the pathogenesis of
myocardial dysfunction. Calcific myocardiopathy and/or severe
metastatic calcifications of the ventricular myocardium has
been observed in advanced renal failure [38, 39]. Drfieke et al
[10] have shown that parathyroidectomy improves the left
ventricular function in dialysis patients and restores the sensi-
tivity to chronotropic action of isoproterenol [40].
An association between secondary hyperparathyroidism and
left ventricular abnormalities in hemodialysis patients is also
suggested from our present study. Cross sectional study of
these patients shows a significant inverse relationship between
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myocardial function is not clear. Recently it has been shown
that the myocardium is a target organ for PTH. The hormone
increases the beating rate of myocardial cells and causes their
death after prolonged hormonal exposure [7]; apparently PTH
stimulates the cyclic AMP production and impairs energy
production, transfer and utilization by myocardial cells [7, 44].
These adverse effects are associated with an increased calcium
uptake, and calcium content of the myocardial cells. Present
data support the hypothesis that parathormone could affect the
heart, but further studies in this area are needed.
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